TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01667198

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and feedback
Description: Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
Study: NCT01320800

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills for Academic and Social Success
Description: 12-week cognitive-behavioral, school-based group intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills for Academic and Social Success
Description: 12-week cognitive-behavioral, school-based group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills for Life
Description: SFL is the Skills for Life Protocol delivered by school counselors.
Study: NCT01121328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cord blood transfusion for preterm neonates
Description: Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cord blood transfusion
Description: After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%).
Study: NCT02326220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01344161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
Study: NCT02953314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Study: NCT02326220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Study: NCT02352636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetotherapy
Description: The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser auriculotherapy
Description: A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser auriculotherapy
Description: A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment.
Study: NCT01613352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory surgery
Description: Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory surgery
Description: Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
Study: NCT01458015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tapentadol, oxycodone
Description: tapentadol pr 100-500 mg oxycodone cr 20-120mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tapentadol, oxycodone
Description: tapentadol pr 100-500 mg oxycodone cr 20-120mg
Study: NCT03186248

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per oral endoscopic myotomy
Description: General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per oral endoscopic myotomy
Description: General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
Study: NCT03970174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Connector care transition module
Description: Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
Study: NCT01872260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day
Study: NCT01858324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational tools
Description: Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
Study: NCT02444962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAVD-implant
Description: hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
Study: NCT04568213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous Acid Gel 0.02%
Description: 0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
Study: NCT02659540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT was delivered in accordance with cohort assignment and institutional practices.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT was delivered in accordance with cohort assignment and institutional practices.
Study: NCT01213940

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pre-bariatric weight loss program
Description: standard 6 month physician directed pre-bariatric weight loss program

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric surgery
Description: bariatric surgery for weight loss
Study: NCT03332875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship Online Program
Description: OurRelationship.com is an online program designed to improve distressed romantic relationships.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship Online Program
Description: OurRelationship.com is an online program designed to improve distressed romantic relationships.
Study: NCT04566185

Intervention type: OTHER
Intervention: FDG PET
Description: IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained.

Intervention type: OTHER
Intervention: CT scan
Description: Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25.

Intervention type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 \*, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium
Study: NCT03750682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity (PA) Intervention
Description: The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Aging Education (HE) Intervention
Description: The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects.
Study: NCT04348357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office visit
Description: Patient comes to the office to receive routine postoperative care
Study: NCT01620788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide / Losartan
Description: 1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide / Losartan
Description: 1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyzaar®
Description: 1 tablet of Hyzaar®, oral, a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyzaar®
Description: 1 tablet of Hyzaar®, oral, a day
Study: NCT01182532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM Syndrome Differentiation and Treatment
Description: 1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~   Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~   Dosage: Adjusting by age and weight of patients. Decoction.~2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western therapy plus TCM treatment
Description: 1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group.
Study: NCT00834379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: 40 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravachol®
Description: 40 mg tablet
Study: NCT02757911

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: X vivo gene therapy
Description: Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
Study: NCT01872260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
Study: NCT03609450

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Primary Care
Description: MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-Dose Comparator
Description: Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
Study: NCT02050555

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02953314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Study: NCT03021265

Intervention type: DRUG
Intervention: T80/A5/H12.5 FDC
Description: Drug
Study: NCT02031731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg/kg Onartuzumab (MetMAb)
Description: 4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
Study: NCT02050555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Koji-extracted beverage fermented with Pediococcus pentosaceus LP28
Study: NCT03230084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urine PDG test
Description: Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
Study: NCT02031731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg/kg Onartuzumab (MetMAb)
Description: 15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
Study: NCT02031731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg/kg Onartuzumab (MetMAb)
Description: 30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
Study: NCT00864045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
Study: NCT00815581

Intervention type: DEVICE
Group type: OTHER
Intervention: photorefraction,cycloautorefraction,cycloretinoscopy
Study: NCT01991457

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Body Irradiation
Study: NCT01432353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFRF4539A
Description: multiple ascending doses
Study: NCT00589654

Intervention type: OTHER
Intervention: Questionnaire
Description: Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
Study: NCT04511702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase with MTX
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase with MTX
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase with MTX
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period